References
1. Rolston K.V.I., Bodey G.P. Infections in patients with cancer. In: Frei E., editor. Cancer Medicine. Hamilton, Ontario: Decker; 2003.
2. Crawford J., Dale D.C., Lyman G.H. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100:228–237. doi: 10.1002/cncr.11882.
3. Casazza A.R., Duvall C.P., Carbone P.P. Infection in lymphoma. Histology, treatment, and duration in relation to incidence and survival. JAMA. 1966;197:710–716. doi: 10.1001/jama.197.9.710.
4. Bodey G.P. Infection in cancer patients. A continuing association. Am J Med. 1986;81:11–26. doi: 10.1016/0002-9343(86)90510-3.
6. Hughes W.T., Armstrong D., Bodey G.P., et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–751. doi: 10.1086/339215.
7. Egerer G., Hensel M., Ho A.D. Infectious complications in chronic lymphoid malignancy. Curr Treat Options Oncol. 2001;2:237–244. doi: 10.1007/s11864-001-0037-1.
8. Samonis G., Kontoyiannis D.P. Infectious complications of purine analog therapy. Curr Opin Infect Dis. 2001;14:409–413. doi: 10.1097/00001432-200108000-00002.
9. Anaissie E.J., Kontoyiannis D.P., O’Brien S., et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 1998;129:559–566. doi: 10.7326/0003-4819-129-7-199810010-00010.
10. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 2004;5:292–302. doi: 10.1016/S1470-2045(04)01467-6.
11. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242. doi: 10.1056/NEJMoa011795.
12. Maness L.J., McSweeney P.A. Treatment options for newly diagnosed patients with chronic myeloid leukemia. Curr Hematol Rep. 2004;3:54–61.
13. Lamanna N., Weiss M. Treatment options for newly diagnosed patients with adult acute lymphoblastic leukemia. Curr Hematol Rep. 2004;3:40–46.
14. Wade J.C., Newton B., Flournoy N., Meyers J.D. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med. 1984;100:823–828. doi: 10.7326/0003-4819-100-6-823.
15. Chang H.Y., Rodriguez V., Narboni G., Bodey G.P., Luna M.A., Freireich E.J. Causes of death in adults with acute leukemia. Medicine. 1976;55:259–268. doi: 10.1097/00005792-197605000-00005.
16. Feld R., Bodey G.P., Rodriguez V., Luna M. Causes of death in patients with malignant lymphoma. Am J Med Sci. 1974;268:97–106. doi: 10.1097/00000441-197408000-00003.
17. Zinner S.H. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis. 1999;29:490–494. doi: 10.1086/598620.
18. Rolston K.V.I., Bodey G.P. Infections in patients with cancer. In: Holland J.F., Frei E., editors. Cancer Medicine. Hamilton, Ontario: Decker; 2000.
19. Wisplinghoff H., Seifert H., Wenzel R.P., Edmond M.B. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36:1103–1110. doi: 10.1086/374339.
20. Anonymous. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990–May 1999, issued June 1999. Am J Infect Control 1999;27:520–532.
21. Farr B.M. Vascular catheter related infections in cancer patients. Surg Oncol Clin N Am. 1995;4:493–503.
22. Rupp M.E., Fey P.D. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs. 2003;63:353–365. doi: 10.2165/00003495-200363040-00002.
23. Safdar N., Maki D.G. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med. 2002;136:834–844. doi: 10.7326/0003-4819-136-11-200206040-00013.
24. Endimiani A., Luzzaro F., Perilli M., et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis. 2004;38:243–251. doi: 10.1086/380645.
25. Schimpff S., Satterlee W., Young V.M., Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971;284:1061–1065. doi: 10.1056/NEJM197105132841904.
26. Chatzinikolaou I., Abi-Said D., Bodey G.P., Rolston K.V., Tarrand J.J., Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes. Arch Intern Med. 2000;160:501–509. doi: 10.1001/archinte.160.4.501.
27. Pagano L., Tacconelli E., Tumbarello M., et al. Bacteremia in patients with hematological malignancies. Analysis of risk factors, etiological agents and prognostic indicators. Haematologica. 1997;82:415–419.
28. Agger W.A., Mardan A. Pseudomonas aeruginosa infections of intact skin. Clin Infect Dis. 1995;20:302–308. doi: 10.1093/clinids/20.2.302.
29. Rolston K.V., Bodey G.P. Pseudomonas aeruginosa infection in cancer patients. Cancer Invest. 1992;10:43–59. doi: 10.3109/07357909209032787.
30. Carmeli Y., Troillet N., Karchmer A.W., Samore M.H. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med. 1999;159:1127–1132. doi: 10.1001/archinte.159.10.1127.
31. Safdar N, Handelsman J, Maki DG. Does combination therapy reduce mortality in gram-negative bacteremia: a meta-analysis. In: 43rd InterScience Conference on Antimicrobial Agents and Chemotherapy, 2003.
32. Spanik S., Trupl J., Kunova A., et al. Risk factors, aetiology, therapy and outcome in 123 episodes of breakthrough bacteraemia and fungaemia during antimicrobial prophylaxis and therapy in cancer patients. J Med Microbiol. 1997;46:517–523. doi: 10.1099/00222615-46-6-517.
33. National Nosocomial Infections Surveillance (NNIS) System Report Data summary from January 1992 to June 2002, issued August 2002. Am J Infect Control. 2002;30:458–475. doi: 10.1067/mic.2002.130032.
34. Wunderink R.G., Rello J., Cammarata S.K., Croos-Dabrera R.V., Kollef M.H. Linezolid vs. vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest. 2003;124:1789–1797.
35. Tunkel A.R., Sepkowitz K.A. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis. 2002;34:1524–1529. doi: 10.1086/340402.
36. Elting L.S., Bodey G.P., Keefe B.H. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis. 1992;14:1201–1207. doi: 10.1093/clinids/14.6.1201.
37. Bilgrami S., Feingold J.M., Dorsky D., Edwards R.L., Clive J., Tutschka P.J. Streptococcus viridans bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1998;21:591–595. doi: 10.1038/sj.bmt.1701140.
38. Cohen J., Donnelly J.P., Worsley A.M., Catovsky D., Goldman J.M., Galton D.A. Septicaemia caused by viridans streptococci in neutropenic patients with leukaemia. Lancet. 1983;2:1452–1454. doi: 10.1016/s0140-6736(83)90799-7.
39. Paganini H., Staffolani V., Zubizarreta P., Casimir L., Lopardo H., Luppino V. Viridans streptococci bacteraemia in children with fever and neutropenia: a case-control study of predisposing factors. Eur J Cancer. 2003;39:1284–1289. doi: 10.1016/s0959-8049(03)00272-7.
40. Ruescher T.J., Sodeifi A., Scrivani S.J., Kaban L.B., Sonis S.T. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer. 1998;82:2275–2281.
41. Richard P., Amador Del Valle G., Moreau P., et al. Viridans streptococcal bacteraemia in patients with neutropenia. Lancet. 1995;345:1607–1609. doi: 10.1016/s0140-6736(95)90117-5.
42. Bostrom B., Weisdorf D. Mucositis and alpha-streptococcal sepsis in bone marrow transplant recipients. Lancet. 1984;1:1120–1121. doi: 10.1016/s0140-6736(84)92530-3.
43. Ringden O., Heimdahl A., Lonnqvist B., Malmborg A.S., Wilczek H. Decreased incidence of viridans streptococcal septicaemia in allogeneic bone marrow transplant recipients after the introduction of acyclovir. Lancet. 1984;1:744. doi: 10.1016/s0140-6736(84)92259-1.
44. Bochud P.Y., Eggiman P., Calandra T., Van Melle G., Saghafi L., Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis. 1994;18:25–31. doi: 10.1093/clinids/18.1.25.
45. Shenep J.L. Viridans-group streptococcal infections in immunocompromised hosts. Int J Antimicrob Agents. 2000;14:129–135. doi: 10.1016/s0924-8579(99)00172-7.
46. Marron A., Carratala J., Alcaide F., Fernandez-Sevilla A., Gudiol F. High rates of resistance to cephalosporins among viridans-group streptococci causing bacteremia in neutropenic cancer patients. J Antimicrob Chemother. 2001;47:87–91. doi: 10.1093/jac/47.1.87.
47. Lyytikainen O., Rautio M., Carlson P., et al. Nosocomial bloodstream infections due to viridans streptococci in haematological and non-haematological patients: species distribution and antimicrobial resistance. J Antimicrob Chemother. 2004;53:631–634. doi: 10.1093/jac/dkh159.
48. Maki D.G., Agger W.A. Enterococcal bacteremia: clinical features, the risk of endocarditis, and management. Medicine. 1988;67:248–269.
49. Anonymous. National Nosocomial Infections Surveillance (NNIS) System Report. Data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003;31:481–498.
50. Lautenbach E., Bilker W.B., Brennan P.J. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol. 1999;20:318–323. doi: 10.1086/501624.
51. Chanock S.J., Pizzo P.A. Fever in the neutropenic host. Infect Dis Clin N Am. 1996;10:777–796. doi: 10.1016/s0891-5520(05)70326-3.
52. Rolston K.V., Bodey G.P. Diagnosis and management of perianal and perirectal infection in the granulocytopenic patient. Curr Clin Top Infect Dis. 1993;13:164–171.
53. Lopez F.A., Sanders C.V. Dermatologic infections in the immunocompromised (non-HIV) host. Infect Dis Clin N Am. 2001;15:671–702. doi: 10.1016/s0891-5520(05)70164-1.
54. File T.M. Necrotizing soft tissue infections. Curr Infect Dis Rep. 2003;5:407–415. doi: 10.1007/s11908-003-0021-y.
55. Stamenkovic I., Lew P.D. Early recognition of potentially fatal necrotizing fasciitis. The use of frozen-section biopsy. N Engl J Med. 1984;310:1689–1693. doi: 10.1056/NEJM198406283102601.
56. Bodey G.P. Unusual presentations of infection in neutropenic patients. Int J Antimicrob Agents. 2000;16:93–95. doi: 10.1016/s0924-8579(00)00241-7.
57. Johnson S., Driks M.R., Tweten R.K., et al. Clinical courses of seven survivors of Clostridium septicum infection and their immunologic responses to alpha toxin. Clin Infect Dis. 1994;19:761–764. doi: 10.1093/clinids/19.4.761.
58. Horton K.M., Corl F.M., Fishman E.K. CT evaluation of the colon: inflammatory disease. Radiographics. 2000;20:399–418. doi: 10.1148/radiographics.20.2.g00mc15399.
59. Schlatter M., Snyder K., Freyer D. Successful nonoperative management of typhlitis in pediatric oncology patients. J Pediatr Surg. 2002;37:1151–1155. doi: 10.1053/jpsu.2002.34461.
60. Rolston K.V. The spectrum of pulmonary infections in cancer patients. Curr Opin Oncol. 2001;13:218–223. doi: 10.1097/00001622-200107000-00002.
61. Okamoto Y., Ribeiro R.C., Srivastava D.K., Shenep J.L., Pui C.H., Razzouk B.I. Viridans streptococcal sepsis: clinical features and complications in childhood acute myeloid leukemia. J Pediatr Hematol Oncol. 2003;25:696–703. doi: 10.1097/00043426-200309000-00005.
62. Maschmeyer G. Pneumonia in febrile neutropenic patients: radiologic diagnosis. Curr Opin Oncol. 2001;13:229–235. doi: 10.1097/00001622-200107000-00004.
63. Rano A., Agusti C., Jimenez P., et al. Pulmonary infiltrates in non-HIV immunocompromised patients: a diagnostic approach using non-invasive and bronchoscopic procedures. Thorax. 2001;56:379–387. doi: 10.1136/thorax.56.5.379.
64. Ninane V. Bronchoscopic invasive diagnostic techniques in the cancer patient. Curr Opin Oncol. 2001;13:236–241. doi: 10.1097/00001622-200107000-00005.
65. Maschmeyer G., Link H., Hiddemann W., Meyer P., Helmerking M., Adam D. Interventional antimicrobial strategy in febrile neutropenic patients. Results of a multicenter study in 1,260 patients with hematological malignancies. The Interventional Antimicrobial Strategy Study Group, Paul Ehrlich Society for Chemotherapy. Onkologie. 1990;13:38–42. doi: 10.1159/000216717.
66. Kyne L., Farrell R.J., Kelly C.P. Clostridium difficile. Gastroenterol Clin N Am. 2001;30:753–777. doi: 10.1016/s0889-8553(05)70209-0.
67. Kyne L., Hamel M.B., Polavaram R., Kelly C.P. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34:346–353. doi: 10.1086/338260.
68. Archibald L.K., Banerjee S.N., Jarvis W.R. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987–2001. J Infect Dis. 2004;189:1585–1589. doi: 10.1086/383045.
69. Pituch H., van Belkum A., van den Braak N., et al. Clindamycin-resistant, toxin A-negative, toxin B-positive Clostridium difficile strains cause antibiotic-associated diarrhea among children hospitalized in a hematology unit. Clin Microbiol Infect. 2003;9:903–904. doi: 10.1046/j.1469-0691.2003.00700.x.
70. Blot E., Escande M.C., Besson D., et al. Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics. J Hosp Infect. 2003;53:187–192. doi: 10.1053/jhin.2002.1356.
71. Hornbuckle K., Chak A., Lazarus H.M., et al. Determination and validation of a predictive model for Clostridium difficile diarrhea in hospitalized oncology patients. Ann Oncol. 1998;9:307–311. doi: 10.1023/a:1008295500932.
72. Komatsu M., Kato H., Aihara M., et al. High frequency of antibiotic-associated diarrhea due to toxin A-negative, toxin B-positive Clostridium difficile in a hospital in Japan and risk factors for infection. Eur J Clin Microbiol Infect Dis. 2003;22:525–529. doi: 10.1007/s10096-003-0992-5.
73. Bartlett J.G. Clostridium difficile infection: pathophysiology and diagnosis. Semin Gastrointest Dis. 1997;8:12–21.
74. Bartlett J.G. Antimicrobial agents implicated in Clostridium difficile toxin-associated diarrhea of colitis. Johns Hopkins Med J. 1981;149:6–9.
75. Delmee M. Laboratory diagnosis of Clostridium difficile disease. Clin Microbiol Infect. 2001;7:411–416. doi: 10.1046/j.1198-743x.2001.00294.x.
76. Kawamoto S., Horton K.M., Fishman E.K. Pseudomembranous colitis: spectrum of imaging findings with clinical and pathologic correlation. Radiographics. 1999;19:887–897. doi: 10.1148/radiographics.19.4.g99jl07887.
77. Bartlett J.G. Management of Clostridium difficile infection and other antibiotic-associated diarrhoeas. Eur J Gastroenterol Hepatol. 1996;8:1054–1061. doi: 10.1097/00042737-199611000-00005.
78. Apisarnthanarak A., Razavi B., Mundy L.M. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis. 2002;35:690–696. doi: 10.1086/342334.
79. Mayfield J.L., Leet T., Miller J., Mundy L.M. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis. 2000;31:995–1000. doi: 10.1086/318149.
80. Simor A.E., Bradley S.F., Strausbaugh L.J., Crossley K., Nicolle L.E. Clostridium difficile in long-term-care facilities for the elderly. Infect Control Hosp Epidemiol. 2002;23:696–703. doi: 10.1086/501997.
81. Crnich C.J., Maki D.G. The role of intravascular devices in sepsis. Current Infect Dis Rep. 2001;3:497–506. doi: 10.1007/s11908-001-0086-4.
82. Pittet D., Tarara D., Wenzel R. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1994;271:1598–1601. doi: 10.1001/jama.271.20.1598.
83. Rello J., Ochagavia A., Sabanes E., et al. Evaluation of outcome of intravenous catheter-related infections in critically ill patients. Am J Respir Crit Care Med. 2000;162:1027–1030. doi: 10.1164/ajrccm.162.3.9911093.
84. Kluger D., Maki D. The relative risk of intravascular device-related bloodstream infections with different types of intravascular devices in adults. A meta-analysis of 206 published studies. Infect Control Hosp Epidemiol. 2000;21:95–96.
85. Maki D.G., Crnich C.J. Line sepsis in the ICU. Semin Respir Crit Care Med. 2002;24:22–36. doi: 10.1055/s-2003-37914.
86. O’Grady N.P., Barie P.S., Bartlett J.G., et al. Practice guidelines for evaluating new fever in critically ill adult patients. Task Force of the Society of Critical Care Medicine and the Infectious Diseases Society of America. Clin Infect Dis. 1998;26:1042–1059. doi: 10.1086/520308.
87. Safdar N., Maki D.G. Inflammation at the insertion site is not predictive of catheter-related bloodstream infection with short-term, noncuffed central venous catheters. Crit Care Med. 2002;30:2632–2635. doi: 10.1097/00003246-200212000-00003.
88. Mermel L.A., Maki D.G. Detection of bacteremia in adults: consequences of culturing an inadequate volume of blood. Ann Intern Med. 1993;119:270–272. doi: 10.7326/0003-4819-119-4-199308150-00003.
89. Gaur A.H., Giannini M.A., Flynn P.M., et al. Optimizing blood culture practices in pediatric immunocompromised patients: evaluation of media types and blood culture volume. Pediatr Infect Dis J. 2003;22:545–552. doi: 10.1097/01.inf.0000069762.44241.0d.
90. Beutz M., Sherman G., Mayfield J., Fraser V.J., Kollef M.H. Clinical utility of blood cultures drawn from central vein catheters and peripheral venipuncture in critically ill medical patients. Chest. 2003;123:854–861. doi: 10.1378/chest.123.3.854.
91. Tacconelli E., Tumbarello M., Pittiruti M., et al. Central venous catheter-related sepsis in a cohort of 366 hospitalised patients. Eur J Clin Microbiol Infect Dis. 1997;16:203–209. doi: 10.1007/BF01709582.
92. Gowardman J.R., Montgomery C., Thirlwell S., et al. Central venous catheter-related bloodstream infections: an analysis of incidence and risk factors in a cohort of 400 patients. Intens Care Med. 1998;24:1034–1039. doi: 10.1007/s001340050712.
93. Bouza E., Burillo A., Munoz P. Catheter-related infections: diagnosis and intravascular treatment. Clin Microbiol Infect. 2002;8:265–274. doi: 10.1046/j.1469-0691.2002.00385.x.
94. Raad I., Hanna H.A., Alakech B., Chatzinikolaou I., Johnson M.M., Tarrand J. Differential time to positivity: a useful method for diagnosing catheter-related bloodstream infections. Ann Intern Med. 2003;140:18–25. doi: 10.7326/0003-4819-140-1-200401060-00007.
95. Moonens F., el Alami S., Van Gossum A., Struelens M.J., Serruys E. Usefulness of gram staining of blood collected from total parenteral nutrition catheter for rapid diagnosis of catheter-related sepsis. J Clin Microbiol. 1994;32:1578–1579. doi: 10.1128/jcm.32.6.1578-1579.1994.
96. Kite P., Dobbins B.M., Wilcox M.H., McMahon M.J. Rapid diagnosis of central-venous-catheter-related bloodstream infection without catheter removal. Lancet. 1999;354:1504–1507. doi: 10.1016/S0140-6736(99)04070-2.
97. Verghese A., Widrich W.C., Arbeit R.D. Central venous septic thrombophlebitis: the role of medical therapy. Medicine. 1985;64:394–400. doi: 10.1097/00005792-198511000-00004.
98. Martinez E., Mensa J., Rovira M., et al. Central venous catheter exchange by guidewire for treatment of catheter-related bacteraemia in patients undergoing BMT or intensive chemotherapy. Bone Marrow Transplantat. 1999;23:41–44. doi: 10.1038/sj.bmt.1701538.
99. Maki D.G. Managment of life-threatening infection in the intensive care unit. In: Prough D.S., editor. Critical Care Medicine: Preoperative Management. 2nd ed. Philadelphia: Lippincott Williams & Williams; 2002. pp. 616–648.
100. Malanoski G.J., Samore M.H., Pefanis A., Karchmer A.W. Staphylococcus aureus catheter-associated bacteremia. Minimal effective therapy and unusual infectious complications associated with arterial sheath catheters. Arch Intern Med. 1995;155:1161–1166. doi: 10.1001/archinte.155.11.1161.
101. Fowler V.G., Jr, Li J., Corey G.R., et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol. 1997;30:1072–1078. doi: 10.1016/s0735-1097(97)00250-7.
102. Nguyen M.H., Peacock J.E., Jr, Tanner D.C., et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med. 1995;155:2429–2435.
103. Rex J.H., Bennett J.E., Sugar A.M., et al. Intravascular catheter exchange and duration of candidemia. Clin Infect Dis. 1995;21:994–996. doi: 10.1093/clinids/21.4.994.
104. Anaissie E.J., Rex J.H., Uzun O., Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med. 1998;104:238–245. doi: 10.1016/s0002-9343(98)00030-8.
105. Messing B., Man F., Colimon R., Thuillier F., Beliah M. Antibiotic lock technique is an effective treatment of bacterial catheter-related sepsis during parenteral nutrition. Clin Nutr. 1990;9:220–224. doi: 10.1016/0261-5614(90)90023-l.
106. Cuntz D., Michaud L., Guimber D., Husson M.O., Gottrand F., Turck D. Local antibiotic lock for the treatment of infections related to central catheters in parenteral nutrition in children. JPEN (J Parenter Enteral Nutr) 2002;26:104–108. doi: 10.1177/0148607102026002104.
107. Guedon C., Nouvellon M., Lalaude O., Lerebours E. Efficacy of antibiotic-lock technique with teicoplanin in Staphylococcus epidermidis catheter-related sepsis during long-term parenteral nutrition. J JPEN (J Parenter Enteral Nutr) 2002;26:109–113. doi: 10.1177/0148607102026002109.
108. Brothers T.E., Von Moll L.K., Niederhuber J.E., Roberts J.A., Walker-Andrews S., Ensminger W.D. Experience with subcutaneous infusion ports in three hundred patients. Surg Gynecol Obstet. 1988;166:295–301.
109. Domingo P., Fontanet A., Sanchez F., Allende L., Vazquez G. Morbidity associated with long-term use of totally implantable ports in patients with AIDS. Clin Infect Dis. 1999;29:346–351. doi: 10.1086/520213.
110. Longuet P., Douard M.C., Maslo C., Benoit C., Arlet G., Leport C. Abstracts and Proceedings from the 35th Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington, DC: ASM Press; 1995. Limited efficacy of antibiotic lock techniques (ALT) in catheter related bacteremia of totally implanted ports (TIP) in HIV infected oncologic patients; p. J5.
111. Crnich C.J., Maki D.G. Infections of vascular devices. In: Cohen J., editor. Infectious Diseases. 2nd ed. Philadelphia: Mosby; 2003. pp. 722–743.
112. Raad I., Davis S., Khan A., Tarrand J., Elting L., Bodey G.P. Impact of central venous catheter removal on the recurrence of catheter-related coagulase-negative staphylococcal bacteremia. Infect Control Hosp Epidemiol. 1992;13:215–221. doi: 10.1086/646512.
113. Mermel L.A., Farr B.M., Sherertz R.J., et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis. 2001;32:1249–1272. doi: 10.1086/320001.
114. Raad I.I., Sabbagh M.F. Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis. 1992;14:75–82. doi: 10.1093/clinids/14.1.75.
115. Rosen A.B., Fowler V.G., Jr., Corey G.R., et al. Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated Staphylococcus aureus bacteremia. Ann Intern Med. 1999;130:810–820. doi: 10.7326/0003-4819-130-10-199905180-00004.
116. O’Grady N.P., Alexander M., Dellinger E.P., et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis. 2002;35:1281–1307. doi: 10.1093/cid/cir257.
117. Crnich C.J., Maki D.G. The promise of novel technology for the prevention of intravascular device-related bloodstream infection. II. Long-term devices. Clin Infect Dis. 2002;34:1362–1368. doi: 10.1086/340105.
118. Henrickson K.J., Axtell R.A., Hoover S.M., et al. Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: a randomized, multicenter, double-blind trial. J Clin Oncol. 2000;18:1269–1278. doi: 10.1200/JCO.2000.18.6.1269.
119. Kuypers D.R., Evenepoel P., Maes B.D., Coosemans W., Pirenne J., Vanrenterghem Y.F. Role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal transplant recipients. Transplant Proc. 2002;34:1164–1170. doi: 10.1016/s0041-1345(02)02812-9.
120. Rasoul-Rockenschaub S., Zielinski C.C., Muller C., Tichatschek E., Popow-Kraupp T., Kunz C. Viral reactivation as a cause of unexplained fever in patients with progressive metastatic breast cancer. Cancer Immunol Immunother. 1990;31:191–195. doi: 10.1007/BF01744736.
121. Perkins J.G., Flynn J.M., Howard R.S., Byrd J.C. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer. 2002;94:2033–2039.
122. Perez-Simon J.A., Kottaridis P.D., Martino R., et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002;100:3121–3127. doi: 10.1182/blood-2002-03-0701.
123. Reusser P. Opportunistic viral infections. In: Powderly W.G., editor. Infectious Diseases. New York: Mosby; 2003. pp. 1169–1181.
124. Dykewicz C.A. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis. 2001;33:139–144. doi: 10.1086/321805.
125. Mitchell P.S., Espy M.J., Smith T.F., et al. Laboratory diagnosis of central nervous system infections with herpes simplex virus by PCR performed with cerebrospinal fluid specimens. J Clin Microbiol. 1997;35:2873–2877. doi: 10.1128/jcm.35.11.2873-2877.1997.
126. Schloss L., van Loon A.M., Cinque P., et al. An international external quality assessment of nucleic acid amplification of herpes simplex virus. J Clin Virol. 2003;28:175–185. doi: 10.1016/s1386-6532(03)00003-9.
127. Gnann J.W. Varicella-zoster virus: atypical presentations and unusual complications. J Infect Dis. 2002;186:S91–S98. doi: 10.1086/342963.
128. Feldman S., Lott L. Varicella in children with cancer. Impact of antiviral therapy and prophylaxis. Pediatrics. 1987;80:465–472.
129. Wood M.J. Viral infections in neutropenia: current problems and chemotherapeutic control. J Antimicrob Chemother. 1998;41:81–93. doi: 10.1093/jac/41.suppl_4.81.
130. Cohen J.I., Brunell P.A., Straus S.E., Krause P.R. Recent advances in varicella-zoster virus infection. Ann Intern Med. 1999;130:922–932. doi: 10.7326/0003-4819-130-11-199906010-00017.
131. Saito S., Yano T., Koga H., Arikawa K., Koyanagi N., Oizumi K. Case of varicella-zoster pneumonia with bronchioalveolar lavage confirmed by the detection of VZV DNA in the bronchial washing by the polymerase chain reaction. Kansenshogaku Zasshi (J the Japanese Association for Infectious Diseases) 1999;73:346–350. doi: 10.11150/kansenshogakuzasshi1970.73.346.
132. Kleinschmidt-DeMasters B.K., Gilden D.H. Varicella-Zoster virus infections of the nervous system: clinical and pathologic correlates. Arch Pathol Lab Med. 2001;125:770–780. doi: 10.5858/2001-125-0770-VZVIOT.
133. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). ( MMWR Morb Mortal Wkly Rep. 1996;45:1–25.
134. Prevention of varicella Updated recommendations of the Advisory Committee on Immunizations Practices (ACIP) MMWR (Morb Mortal Wkly Rep) 1999;48:1–5.
135. Patel R., Paya C.V. Infections in solid-organ transplant recipients. Clin Microbiol Rev. 1997;10:86–124. doi: 10.1128/cmr.10.1.86.
136. Konoplev S., Champlin R.E., Giralt S., et al. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant. 2001;27:877–881. doi: 10.1038/sj.bmt.1702877.
137. Nguyen Q., Estey E., Raad I., et al. Cytomegalovirus pneumonia in adults with leukemia: an emerging problem. Clin Infect Dis. 2001;32:539–545. doi: 10.1086/318721.
138. Meyers J.D., Ljungman P., Fisher L.D. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J Infect Dis. 1990;162:373–380. doi: 10.1093/infdis/162.2.373.
139. Enright H., Haake R., Weisdorf D., et al. Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy. Transplantation. 1993;55:1339–1346. doi: 10.1097/00007890-199306000-00024.
140. Goodrich J.M., Bowden R.A., Fisher L., Keller C., Schoch G., Meyers J.D. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 193;118:173–178. doi: 10.7326/0003-4819-118-3-199302010-00003.
141. Boeckh M., Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol. 1998;11:533–554. doi: 10.1128/cmr.11.3.533.
142. Cortez K.J., Fischer S.H., Fahle G.A., et al. Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients. J Infect Dis. 2003;188:967–972. doi: 10.1086/378413.
143. Reed E.C., Bowden R.A., Dandliker P.S., Lilleby K.E., Meyers J.D. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med. 1988;109:783–788. doi: 10.7326/0003-4819-109-10-783.
144. Machado C.M., Dulley F.L., Boas L.S., et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy. Bone Marrow Transplant. 2000;26:413–417. doi: 10.1038/sj.bmt.1702526.
145. Goodrich J.M., Mori M., Gleaves C.A., et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991;325:1601–1607. doi: 10.1056/NEJM199112053252303.
146. Schmidt G.M., Horak D.A., Niland J.C., Duncan S.R., Forman S.J., Zaia J.A. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med. 1991;324:1005–1011. doi: 10.1056/NEJM199104113241501.
147. Singhal S., Powles R., Treleaven J., et al. Cytomegaloviremia after autografting for leukemia: clinical significance and lack of effect on engraftment. Leukemia. 1997;117:835–838. doi: 10.1038/sj.leu.2400672.
148. Baker K.S., DeFor T.E., Burns L.J., Ramsay N.K., Neglia J.P., Robison L.L. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol. 2003;21:1352–1358. doi: 10.1200/JCO.2003.05.108.
149. Loren A.W., Porter D.L., Stadtmauer E.A., Tsai D.E. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant. 2003;31:145–155. doi: 10.1038/sj.bmt.1703806.
150. Cohen J.I. Epstein-Barr virus infection. N Engl J Med. 2000;343:481–492. doi: 10.1056/NEJM200008173430707.
151. Singh N., Paterson D.L. Encephalitis caused by human herpesvirus-6 in transplant recipients: relevance of a novel neurotropic virus. Transplantation. 2000;69:2474–2479. doi: 10.1097/00007890-200006270-00002.
152. Cole P.D., Stiles J., Boulad F., et al. Successful treatment of human herpesvirus 6 encephalitis in a bone marrow transplant recipient. Clin Infect Dis. 1998;27:653–654. doi: 10.1086/517145.
153. Couch R.B., Englund J.A., Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med. 1997;102:2–9. doi: 10.1016/S0002-9343(97)00003-X.
154. Englund J.A., Anderson L.J., Rhame F.S. Nosocomial transmission of respiratory syncytial virus in immunocompromised adults. J Clin Microbiol. 1991;29:115–119. doi: 10.1128/jcm.29.1.115-119.1991.
155. Whimbey E., Champlin R.E., Couch R.B., et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis. 1996;22:778–782. doi: 10.1093/clinids/22.5.778.
156. Whimbey E., Couch R.B., Englund J.A., et al. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis. 1995;21:376–379. doi: 10.1093/clinids/21.2.376.
157. Hindiyeh M., Hillyard D.R., Carroll K.C. Evaluation of the Prodesse Hexaplex multiplex PCR assay for direct detection of seven respiratory viruses in clinical specimens. Am J Clin Pathol. 2001;116:218–224. doi: 10.1309/F1R7-XD6T-RN09-1U6L.
158. Ison M.G., Hayden F.G. Viral infections in immunocompromised patients: what’s new with respiratory viruses? Curr Opin Infect Dis. 2002;15:355–367. doi: 10.1097/00001432-200208000-00002.
159. Nichols W.G., Gooley T., Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant. 2001;7:11S–15S. doi: 10.1053/bbmt.2001.v7.pm11777098.
160. Salgado C.D., Farr B.M., Hall K.K., Hayden F.G. Influenza in the acute hospital setting. Lancet Infect Dis. 2002;2:145–155. doi: 10.1016/s1473-3099(02)00221-9.
161. Hall C.B. Nosocomial respiratory syncytial virus infections: the “Cold War” has not ended. Clin Infect Dis. 2000;31:590–596. doi: 10.1086/313960.
162. Bridges C.B., Harper S.A., Fukuda K., et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Morb Mortal Wkly Rep Recommend Rep. 2003;52:1–34.
163. Wheat L.J., Goldman M., Sarosi G.A. Fungal infections in the immunocompromised host. In: Young L.S., editor. Clinical Approach to Infection in the Compromised Host. 4th ed. New York: Kluwer/Plenum; 2002. pp. 215–247.
164. Colombo A.L., Perfect J., DiNubile M., et al. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis. 2003;22:470–474. doi: 10.1007/s10096-003-0973-8.
165. Rex J.H., Walsh T.J., Sobel J.D., et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis. 2000;30:662–678. doi: 10.1086/313749.
166. National Nosocomial Infections Surveillance (NNIS) System Report Data summary from January 1992 to June 2002, issued August 2002. AJIC Am J Infect Control. 2002;30:458–475. doi: 10.1067/mic.2002.130032.
167. Pittet D., Li N., Woolson R., Wenzel R. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin Infect Dis. 1997;24:1068–1078. doi: 10.1086/513640.
168. Viscoli C., Girmenia C., Marinus A., et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC) Clin Infect Dis. 1999;28:1071–1079. doi: 10.1086/514731.
169. Wey S.B., Mori M., Pfaller M.A., Woolson R.F., Wenzel R.P. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med. 1989;149:2349–2353.
170. Walsh T.J., Rex J.H. All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. Clin Infect Dis. 2002;34:600–602. doi: 10.1086/338715.
171. Hockey L.J., Fujita N.K., Gibson T.R., Rotrosen D., Montgomerie J.Z., Edwards J.E., Jr. Detection of fungemia obscured by concomitant bacteremia: in vitro and in vivo studies. J Clin Microbiol. 1982;16:1080–1085. doi: 10.1128/jcm.16.6.1080-1085.1982.
172. Munoz P., Bernaldo de Quiros J.C., Berenguer J., Rodriguez Creixems M., Picazo J.J., Bouza E. Impact of the BACTEC NR system in detecting Candida fungemia. J Clin Microbiol. 1990;28:639–641. doi: 10.1128/jcm.28.3.639-641.1990.
173. Pappas P.G., Rex J.H., Sobel J.D., et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38:161–189. doi: 10.1086/380796.
174. Rex J.H., Bennett J.E., Sugar A.M., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med. 1994;331:1325–1330. doi: 10.1056/NEJM199411173312001.
175. Phillips P., Shafran S., Garber G., et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis. 1997;16:337–345. doi: 10.1007/BF01726360.
176. Mora-Duarte J., Betts R., Rotstein C., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020–2029. doi: 10.1056/NEJMoa021585.
177. Thaler M., Pastakia B., Shawker T.H., O’Leary T., Pizzo P.A. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med. 1988;108:88–100. doi: 10.7326/0003-4819-108-1-88.
178. Denning D.W. Invasive aspergillosis. Clin Infect Dis. 1998;26:781–805. doi: 10.1086/513943.
179. Baddley J.W., Stroud T.P., Salzman D., Pappas P.G. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis. 2001;32:1319–1324. doi: 10.1086/319985.
180. Marr K.A., Carter R.A., Boeckh M., Martin P., Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 202;100:4358–4366. doi: 10.1182/blood-2002-05-1496.
181. Allo M.D., Miller J., Townsend T., Tan C. Primary cutaneous aspergillosis associated with Hickman intravenous catheters. N Engl J Med. 1987;317:1105–1108. doi: 10.1056/NEJM198710293171802.
182. Warris A., Gaustad P., Meis J.F., Voss A., Verweij P.E., Abrahamsen T.G. Recovery of filamentous fungi from water in a paediatric bone marrow transplantation unit. J Hosp Infect. 2001;47:143–148. doi: 10.1053/jhin.2000.0876.
183. Denning D.W. Therapeutic outcomes in invasive aspergillosis. Clin Infect Dis. 1996;23:608–615. doi: 10.1093/clinids/23.3.608.
184. Denning D.W., Marinus A., Cohen J., et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. J Infect. 1998;37:173–180. doi: 10.1016/s0163-4453(98)80173-4.
185. Kuhlman J.E., Fishman E.K., Siegelman S.S. Invasive pulmonary aspergillosis in acute leukemia: characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis. Radiology. 1985;157:611–614. doi: 10.1148/radiology.157.3.3864189.
186. Curtis A.M., Smith G.J., Ravin C.E. Air crescent sign of invasive aspergillosis. Radiology. 1979;133:17–21. doi: 10.1148/133.1.17.
187. Perfect J.R., Cox G.M., Lee J.Y., et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis. 2001;33:1824–1833. doi: 10.1086/323900.
188. Maetens J., Verhaegen J., Lagrou K., Van Eldere J., Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 2001;97:1604–1610. doi: 10.1182/blood.v97.6.1604.
189. Denning D.W. Echinocandins: a new class of antifungal. J Antimicrob Chemother. 2002;49:889–891. doi: 10.1093/jac/dkf045.
190. Patterson T.F., Kirkpatrick W.R., White M., et al. Invasive aspergillosis: a disease spectrum, treatment practices, and outcomes. Medicine. 2000;79:250–260. doi: 10.1097/00005792-200007000-00006.
191. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408–415. doi: 10.1056/NEJMoa020191.
192. Manavathu E.K., Alangaden G.J., Chandrasekar P.H. Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J Antimicrob Chemother. 2003;51:1423–1425. doi: 10.1093/jac/dkg242.
193. Dannaoui E., Lortholary O., Dromer F. In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother. 2004;48:970–978. doi: 10.1128/AAC.48.3.970-978.2004.
194. Segal B.H., Walsh T.J. Opportunistic fungal infections. In: Powderly W.G., editor. Infectious Diseases. New York: Mosby; 2003. pp. 1155–1167.
195. Leong K.W., Crowley B., White B., et al. Cutaneous mucormycosis due to Absidia corymbifera occurring after bone marrow transplantation. Bone Marrow Transplant. 1997;19:513–515. doi: 10.1038/sj.bmt.1700667.
196. Fleming R.V., Walsh T.J., Anaissie E.J. Emerging and less common fungal pathogens. Infect Dis Clin N Am. 2002;16:915–933. doi: 10.1016/s0891-5520(02)00041-7.
197. Anaissie E.J., Penzak S.R., Dignani M.C. The hospital water supply as a source of nosocomial infections: a plea for action. Arch Intern Med. 2002;162:1483–1492. doi: 10.1001/archinte.162.13.1483.
198. Raad I., Tarrand J., Hanna H., et al. Epidemiology, molecular mycology, and environmental sources of Fusarium infection in patients with cancer. Infect Control Hosp Epidemiol. 2002;23:532–537. doi: 10.1086/502102.
199. Boutati E.I., Anaissie E.J. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management. Blood. 1997;90:999–1008.
200. Walsh T.J., Groll A.H. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transplant Infect Dis. 1999;1:247–261. doi: 10.1034/j.1399-3062.1999.010404.x.
201. Sickles E.A., Greene W.H., Wiernik P.H. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 1975;135:715–719.
202. Siegel D.L., Edelstein P.H., Nachamkin I. Inappropriate testing for diarrheal diseases in the hospital. JAMA. 1990;263:979–982.
203. Furno P., Bucaneve G., Del Favero A. Monotherapy or aminogly-coside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis. 2002;2:231–242. doi: 10.1016/s1473-3099(02)00241-4.
204. Paul M., Soares-Weiser K., Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ. 2003;326:1111. doi: 10.1136/bmj.326.7399.1111.
205. Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev 2003:CD003038.
206. Smith C.E., Tillman B.S., Howell A.W., Longfield R.N., Jorgensen J.H. Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extended-spectrum beta-lactamase. Antimicrob Agents Chemother. 1990;34:1290–1293. doi: 10.1128/aac.34.6.1290.
207. Fleischhack G., Hartmann C., Simon A., et al. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother. 2001;47:841–853. doi: 10.1093/jac/47.6.841.
208. Giamarellou H., Bassaris H.P., Petrikkos G., et al. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrob Agents Chemother. 2000;44:3264–3271. doi: 10.1128/aac.44.12.3264-3271.2000.
209. Livermore D.M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002;34:634–640. doi: 10.1086/338782.
210. Peacock J.E., Herrington D.A., Wade J.C., et al. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial. Ann Intern Med. 2002;137:77–87. doi: 10.7326/0003-4819-137-2-200207160-00005.
211. Rubin M., Hathorn J.W., Marshall D., Gress J., Steinberg S.M., Pizzo P.A. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med. 1988;108:30–35. doi: 10.7326/0003-4819-108-1-30.
212. Cometta A., Kern W.V., De Bock R., et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis. 2003;37:382–389. doi: 10.1086/376637.
213. Maki D.G. Management of life-threatening infection in the intensive care unit. In: Murray M.J., Coursin D.B., editors. Critical Care Medicine: Preoperative Management. Philadelphia: Lippincott, Williams & Wilkins; 2002.
214. Rybak M.J. Therapeutic options for gram-positive infections. J Hosp Infect. 2001;49(suppl A):S25–S32. doi: 10.1016/s0195-6701(01)90031-3.
215. Hughes W.T., Armstrong D., Bodey G.P., et al. From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis. 1990;161:381–396. doi: 10.1093/infdis/161.3.381.
216. Talcott J.A., Finberg R., Mayer R.J., Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med. 1988;148:2561–2568.
217. Talcott J.A., Siegel R.D., Finberg R., Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. 1992;10:316–322. doi: 10.1200/JCO.1992.10.2.316.
218. Klastersky J., Paesmans M., Rubenstein E.B., et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–3051. doi: 10.1200/JCO.2000.18.16.3038.
219. DeGregorio M.W., Lee W.M., Linker C.A., Jacobs R.A., Ries C.A. Fungal infections in patients with acute leukemia. Am J Med. 1982;73:543–548. doi: 10.1016/0002-9343(82)90334-5.
220. Davies S.V., Murray J.A. Amphotericin and abolition of fever in neutropenic sepsis. Br Med J. 1989;299:1339–1340. doi: 10.1136/bmj.299.6711.1339-c.
221. Pizzo P.A., Ribichaud K.J., Gill F.A., Witebsky F.G. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982;72:101–111. doi: 10.1016/0002-9343(82)90594-0.
222. Stein R.S., Kayser J., Flexner J.M. Clinical value of empirical amphotericin B in patients with acute myelogenous leukemia. Cancer. 1982;50:2247–2251. doi: 10.1002/1097-0142(19821201)50:11<2247::aid-cncr2820501102>3.0.co;2-7.
223. Subira M., Martino R., Gomez L., Marti J.M., Estany C., Sierra J. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies: a randomized, controlled trial. Eur J Haematol. 2004;72:342–347. doi: 10.1111/j.1600-0609.2004.00239.x.
224. Walsh T.J., Finberg R.W., Arndt C., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 1999;340:764–771. doi: 10.1056/NEJM199903113401004.
225. Wingard J.R., White M.H., Anaissie E., et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis. 2000;31:1155–1163. doi: 10.1086/317451.
226. Winston D.J., Hathorn J.W., Schuster M.G., et al. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med. 2000;108:282–289. doi: 10.1016/s0002-9343(99)00457-x.
227. Boogaerts M., Winston D.J., Bow E.J., et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med. 2001;135:412–422. doi: 10.7326/0003-4819-135-6-200109180-00010.
228. Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225–234. doi: 10.1056/NEJM200201243460403.
229. Powers J.H., Dixon C.A., Goldberger M.J. Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:289–290. doi: 10.1056/NEJM200201243460414.
230. Aquino V.M., Tkaczewski I., Buchanan G.R. Early discharge of low-risk febrile neutropenic children and adolescents with cancer. Clin Infect Dis. 1997;25:74–78. doi: 10.1086/514512.
231. Joshi J.H., Schimpff S.C., Tenney J.H., Newman K.A., de Jongh C.A. Can antibacterial therapy be discontinued in persistently febrile granulocytopenic cancer patients? Am J Med. 1984;76:450–457. doi: 10.1016/0002-9343(84)90664-8.
232. Talbot G.H., Provencher M., Cassileth P.A. Persistent fever after recovery from granulocytopenia in acute leukemia. Arch Intern Med. 1988;148:129–135.
233. Flynn P.M., Shenep J.L., Crawford R., Hughes W.T. Use of abdominal computed tomography for identifying disseminated fungal infection in pediatric cancer patients. Clin Infect Dis. 1995;20:964–970. doi: 10.1093/clinids/20.4.964.
234. Elting L.S., Rubenstein E.B., Rolston K.V., Bodey G.P. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997;25:247–259. doi: 10.1086/514550.
235. Clark OA, Lyman G, Castro AA, Clark LG, Djulbegovic B. Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev 2003:CD003039.
236. Link H., Bohme A., Cornely O.A., et al. Antimicrobial therapy of unexplained fever in neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society) Ann Hematol. 2003;82(suppl 2):S105–S117. doi: 10.1007/s00277-003-0764-4.
237. Lucas KG. Another look at granulocyte transfusions in neutropenic patients with cancer. Infect Med 1996;13.
238. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–1377. doi: 10.1056/NEJMoa010307.
239. Connors A.F., Jr, Speroff T., Dawson N.V., et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA. 1996;276:889–897. doi: 10.1001/jama.276.11.889.
240. Sandham J.D., Hull R.D., Brant R.F., et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med. 2003;348:5–14. doi: 10.1056/NEJMoa021108.
241. Annane D., Sebille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288:862–871. doi: 10.1001/jama.288.7.862.
242. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709. doi: 10.1056/NEJM200103083441001.
243. Shelton B.K. Evidence-based care for the neutropenic patient with leukemia. Semin Oncol Nurs. 2003;19:133–141. doi: 10.1016/s0749-2081(03)00026-3.
244. Nauseef W.M., Maki D.G. A study of the value of simple protective isolation in patients with granulocytopenia. N Engl J Med. 1981;304:448–453. doi: 10.1056/NEJM198102193040802.
245. Boyce J.M. Understanding and controlling methicillin-resistant Staphylococcus aureus infections. Infect Control Hosp Epidemiol. 2001;23(9):485–487. doi: 10.1086/502092.
246. Wenzel R.P., Reagan D.R., Bertino J.S., Jr, Baron E.J., Arias K. Methicillin-resistant Staphylococcus aureus outbreak: a consensus panel’s definition and management guidelines. Am J Infect Control. 1998;26:102–110. doi: 10.1016/s0196-6553(98)80029-1.
247. Garner J.S. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1996;17:53–80. doi: 10.1086/647190.
248. Fridkin S.K. Increasing prevalence of antimicrobial resistance in intensive care units. Crit Care Med. 2001;29:N64–N68. doi: 10.1097/00003246-200104001-00002.
249. Warren D.K., Fraser V.J. Infection control measures to limit antimicrobial resistance. Crit Care Med. 2001;29:N128–N134. doi: 10.1097/00003246-200104001-00013.
250. Muto C.A., Jernigan J.A., Ostrowsky B.E., et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol. 2003;24:362–386. doi: 10.1086/502213.
251. Jernigan J.A., Clemence M.A., Stott G.A., et al. Control of methicillin-resistant Staphylococcus aureus at a university hospital: one decade later. Infect Control Hospital Epidemiol. 1995;16:686–696. doi: 10.1086/647042.
252. Farr B.M. Hospital wards spreading vancomycin-resistant enterococci to intensive care units: returning coals to Newcastle. Crit Care Med. 1998;26:1942–1943. doi: 10.1097/00003246-199812000-00008.
253. Walsh T.J., Vlahov D., Hansen S.L., et al. Prospective microbiologic surveillance in control of nosocomial methicillin-resistant Staphylococcus aureus. Infect Control. 1987;8:7–14. doi: 10.1017/s0195941700066923.
254. Jernigan J.A., Titus M.G., Groschel D.H., Getchell-White S., Farr B.M. Effectiveness of contact isolation during a hospital outbreak of methicillin-resistant Staphylococcus aureus. Am J Epidemiol. 1996;143:496–504. doi: 10.1093/oxfordjournals.aje.a008770.
255. Murray-Leisure K.A., Geib S., Graceley D., et al. Control of epidemic methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol. 1990;11:343–350. doi: 10.1086/646185.
256. Morris J.G., Jr, Shay D.K., Hebden J.N., et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med. 1995;123:250–259. doi: 10.7326/0003-4819-123-4-199508150-00002.
257. Goetz A.M., Rihs J.D., Wagener M.M., Muder R.R. Infection and colonization with vancomycin-resistant Enterococcus faecium in an acute care Veterans Affairs Medical Center: a 2-year survey. Am J Infect Control. 1998;26:558–562. doi: 10.1053/ic.1998.v26.a86286.
258. Ostrowsky B.E., Trick W.E., Sohn A.H., et al. Control of vancomycin-resistant enterococcus in health care facilities in a region. N Engl J Med. 2001;344:1427–1433. doi: 10.1056/NEJM200105103441903.
259. Kotilainen P., Routamaa M., Peltonen R., et al. Eradication of methicillin-resistant Staphylococcus aureus from a health center ward and associated nursing home. Arch Intern Med. 2001;161:859–863. doi: 10.1001/archinte.161.6.859.
260. Zuckerman R.A., Steele L., Venezia R.A., Tobin E.H. Undetected vancomycin-resistant Enterococcus in surgical intensive care unit patients. Infect Control Hosp Epidemiol. 1999;20:685–686. doi: 10.1086/501565.
261. Maki DG, Zilz MA, McComick R. The effectiveness of using preemptive barrier precautions routinely (protective isolation) in all high-risk patients to prevent nosocomial infection with resistant organisms, especially MRSA, VRE and C. difficile . In: Thirty-fourth Annual Meeting of the Infectious Disease Society of North America, 1996, New Orleans, Louisiana.
262. van Voorhis J, Destefano L, Sobek S, et al. Impact of barrier precautions and cohorting on a monoclonal outbreak of vancomycin-resistant Enterococcus faecium (VRE). In: Society for Healthcare Epidemiology of America, 1997.
263. Klein B.S., Perloff W.H., Maki D.G. Reduction of nosocomial infection during pediatric intensive care by protective isolation. N Engl J Med. 1989;320:1714–1721. doi: 10.1056/NEJM198906293202603.
264. Slota M., Green M., Farley A., Janosky J., Carcillo J. The role of gown and glove isolation and strict handwashing in the reduction of nosocomial infection in children with solid organ transplantation. Crit Care Med. 2001;29:405–412. doi: 10.1097/00003246-200102000-00034.
265. Safdar N, Marx J, Meyer N, Maki DG. The effectiveness of preemptive enhanced barrier precautions for controlling MRSA in a burn unit. In: 43rd InterScience Conference on Antimicrobial Agents and Chemotherapy, 2003, Chicago, Illinois.
266. Srinivasan A., Song X., Ross T., Merz W., Brower R., Perl T.M. A prospective study to determine whether cover gowns in addition to gloves decrease nosocomial transmission of vancomycin-resistant enterococci in an intensive care unit. Infect Control Hosp Epidemiol. 2002;23:424–428. doi: 10.1086/502079.
267. Montecalvo M.A., Jarvis W.R., Uman J., et al. Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting. Ann Intern Med. 1999;131:269–272. doi: 10.7326/0003-4819-131-4-199908170-00006.
268. Koss WG, Khalili TM, Lemus JF, Chelly MM, Margulies DR, Shabot MM. Nosocomial pneumonia is not prevented by protective contact isolation in the surgical intensive care unit. Am Surg 2001;67.
269. Lew M.A., Kehoe K., Ritz J., et al. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol. 1995;13:239–250. doi: 10.1200/JCO.1995.13.1.239.
270. Prentice H.G., Hann I.M., Nazareth B., Paterson P., Bhamra A., Kibbler C.C. Oral ciprofloxacin plus colistin: prophylaxis against bacterial infection in neutropenic patients. A strategy for the prevention of emergence of antimicrobial resistance. Br J Haematol. 2001;115:46–52. doi: 10.1046/j.1365-2141.2001.03034.x.
271. Cruciani M., Malena M., Bosco O., Nardi S., Serpelloni G., Mengoli C. Reappraisal with meta-analysis of the addition of grampositive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol. 2003;21:4127–4137. doi: 10.1200/JCO.2003.01.234.
272. Bow E.J., Laverdiere M., Lussier N., Rotstein C., Cheang M.S., Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta-analysis of randomized-controlled clinical trials. Cancer. 2002;94:3230–3246. doi: 10.1002/cncr.10610.
273. Kanda Y., Yamamoto R., Chizuka A., et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer. 2000;89:1611–1625.
274. Wiederhold N.P., Lewis R.E., Kontoyiannis D.P. Invasive aspergillosis in patients with hematologic malignancies. Pharmacotherapy. 2003;23:1592–1610. doi: 10.1592/phco.23.15.1592.31965.
275. Fukuda T., Boeckh M., Carter R.A., et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood. 2003;102:827–833. doi: 10.1182/blood-2003-02-0456.
276. Goodman J.L., Winston D.J., Greenfield R.A., et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845–851. doi: 10.1056/NEJM199203263261301.
277. MacMillan M.L., Goodman J.L., DeFor T.E., Weisdorf D.J. Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med. 2002;112:369–379. doi: 10.1016/s0002-9343(01)01127-5.
278. Glasmacher A., Prentice A., Gorschluter M., et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a metaanalysis of 3,597 patients. J Clin Oncol. 2003;21:4615–4626. doi: 10.1200/JCO.2003.04.052.
279. Mattiuzzi G.N., Kantarjian H., Faderl S., et al. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer. 2004;100:581–589. doi: 10.1002/cncr.11936.
280. Bodey G.P., Anaissie E.J., Elting L.S., Estey E., O’Brien S., Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer. 1994;73:2099–2106. doi: 10.1002/1097-0142(19940415)73:8<2099::aid-cncr2820730814>3.0.co;2-n.
281. Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225–234. doi: 10.1056/NEJM200201243460403.
282. Cornely O.A., Bohme A., Buchheidt D., et al. Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) Ann Hematol. 2003;82(suppl 2):S186–S200. doi: 10.1007/s00277-003-0773-3.
283. Kish M.A. Guide to development of practice guidelines. Clin Infect Dis. 2001;32:851–854. doi: 10.1086/319366.
284. Minotti V., Gentile G., Bucaneve G., et al. Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment. Support Care Cancer. 1999;7:134–139. doi: 10.1007/s005200050243.
285. Paganini H.R., Sarkis C.M., De Martino M.G., et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer. 2000;88:2848–2852. doi: 10.1002/1097-0142(20000615)88:12<2848::aid-cncr27>3.0.co;2-2.
286. Paganini H., Rodriguez-Brieshcke T., Zubizarreta P., et al. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. Cancer. 2001;91:1563–1567. doi: 10.1002/1097-0142(20010415)91:8<1563::aid-cncr1166>3.0.co;2-c.
287. Paganini H., Gomez S., Ruvinsky S., et al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina. Cancer. 2003;97:1775–1780. doi: 10.1002/cncr.11251.
288. Shenep J.L., Flynn P.M., Baker D.K., et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clin Infect Dis. 2001;32:36–43. doi: 10.1086/317552.
289. Mullen C.A., Petropoulos D., Roberts W.M., et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer. 1999;86:126–134.
290. Hidalgo M., Hornedo J., Lumbreras C., et al. Outpatient therapy with oral ciprofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer. 1999;85:213–219.
291. Innes H.E., Smith D.B., O’Reilly S.M., Clark P.I., Kelly V., Marshall E. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer. 2003;89:43–49. doi: 10.1038/sj.bjc.6600993.
292. Petrilli A.S., Dantas L.S., Campos M.C., Tanaka C., Ginani V.C., Seber A. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Med Pediatr Oncol. 2000;34:87–91. doi: 10.1002/(sici)1096-911x(200002)34:2<87::aid-mpo2>3.0.co;2-f.
293. Freifeld A., Marchigiani D., Walsh T., et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med. 1999;341:305–311. doi: 10.1056/NEJM199907293410501.
294. Kern W.V., Cometta A., De Bock R., Langenaeken J., Paesmans M., Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1999;341:312–318. doi: 10.1056/NEJM199907293410502.
295. Engervall P., Gunther G., Ljungman P., et al. Trimethoprim-sulfamethoxazole plus amikacin versus ceftazidime monotherapy as empirical treatment in patients with neutropenia and fever. Scand J Infect Dis. 1996;28:297–303. doi: 10.3109/00365549609027177.
296. Velasco E., Costa M.A., Martins C.A., Nucci M. Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. Am J Clin Oncol. 1995;18:429–435. doi: 10.1097/00000421-199510000-00014.
297. Malik I.A., Abbas Z., Karim M. Randomised comparison of oral ciprofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet. 1992;339:1092–1096. doi: 10.1016/0140-6736(92)90674-r.
298. Rubenstein E.B., Rolston K., Benjamin R.S., et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer. 1993;71:3640–3646. doi: 10.1002/1097-0142(19930601)71:11<3640::aid-cncr2820711128>3.0.co;2-h.
299. Johnson P.R., Liu Yin J.A., Tooth J.A. A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients. J Antimicrob Chemother. 1992;30:203–214. doi: 10.1093/jac/30.2.203.
300. Flaherty J.P., Waitley D., Edlin B., et al. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. Am J Med. 1989;87:278S–282S. doi: 10.1016/0002-9343(89)90080-6.
301. Chan C.C., Oppenheim B.A., Anderson H., Swindell R., Scarffe J.H. Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients. Antimicrob Agents Chemother. 1989;33:87–91. doi: 10.1128/aac.33.1.87.
302. Rolston KVI, Rubenstein E, Elting L. Ambulatory management of febrile episodes in low-risk patients. In: 35th InterScience Conference of Antimicrobial Agents and Chemotherapy, 1995, San Francisco, California.
303. Cometta A., Zinner S., de Bock R., et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother. 1995;39:445–452. doi: 10.1128/aac.39.2.445.
304. Cometta A., Calandra T., Gaya H., et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother. 1996;40:1108–1115. doi: 10.1128/aac.40.5.1108.